Catherine J. Mummery
0000-0002-6739-0803
Publication & Citation Trends
Publications
0 total
Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study
Cited by 2
Semantic Scholar
Treatment for Alzheimer's disease.
Cited by 15
Semantic Scholar
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
Cited by 15
Semantic Scholar
Treatment‐related amyloid clearance (TRAC): a framework to characterize patients in the era of anti‐amyloid therapies
Cited by 3
Semantic Scholar
Acquired comedomal plaques in a middle aged female.
Cited by 0
Semantic Scholar
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease OA
Cited by 20
Semantic Scholar
Research Topics
Alzheimer's disease research and treatments
(51)
Dementia and Cognitive Impairment Research
(46)
Health Systems, Economic Evaluations, Quality of Life
(12)
Cholinesterase and Neurodegenerative Diseases
(12)
Neurobiology of Language and Bilingualism
(11)
Affiliations
University College Hospital
University College London Hospitals NHS Foundation Trust
Wellcome Centre for Human Neuroimaging
City, University of London
MRC Cognition and Brain Sciences Unit